Clinical trial
The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study
NCT00400231 · University of Pennsylvania, Other · Completed
Key facts
| NCT number | NCT00400231 |
|---|---|
| Title | The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study |
| Official title | The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study |
| Lead sponsor | University of Pennsylvania, Other |
| Collaborators | Abbott Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome x |
| Intervention type | Drug |
| Interventions | Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo |
| Enrollment | 124 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Nov 16, 2006 |
| Last update posted | Mar 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: